July 11, 2023
6 min watch
Save
VIDEO: Praise for oral, topical JAK inhibitors for atopic dermatitis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio video exclusive from Maui Derm NP+PA Summer, meeting program director George Martin, MD, discusses highlights in the treatment of psoriasis.
Among the many treatments discussed, deucravacitinib stands out as highly effective, Martin said.
“The beauty is, [deucravacitinib] has not inherited the legacy, the black box warning, that comes with other JAK inhibitors,” Martin said.
“It’s clear that inhibition of TYK2 is a real target,” he added.
In addition, Martin discusses what's in the pipeline, including the monoclonal antibody bimekizumab.
“We are seeing the highest efficacy we’ve ever seen for monoclonal antibodies for psoriasis,” Martin said.